165 related articles for article (PubMed ID: 31428819)
1. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
Xing M; Wang J; Yang Q; Wang Y; Li J; Xiong J; Zhou S
Cancer Chemother Pharmacol; 2019 Oct; 84(4):861-872. PubMed ID: 31428819
[TBL] [Abstract][Full Text] [Related]
2. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.
Liu T; Xiong J; Yi S; Zhang H; Zhou S; Gu L; Zhou M
Oncogene; 2017 Mar; 36(12):1678-1686. PubMed ID: 27617579
[TBL] [Abstract][Full Text] [Related]
3. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
Zhang X; Su X; Guo Z; Jiang X; Li X
J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
[TBL] [Abstract][Full Text] [Related]
4. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.
Suzuki A; Toi M; Yamamoto Y; Saji S; Muta M; Tominaga T
Jpn J Cancer Res; 1998 Feb; 89(2):221-7. PubMed ID: 9548451
[TBL] [Abstract][Full Text] [Related]
5. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
6. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
7. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
8. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
10. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
11. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
[TBL] [Abstract][Full Text] [Related]
12. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
Qi M; Yi X; Yue B; Huang M; Zhou S; Xiong J
Breast Cancer Res; 2023 May; 25(1):55. PubMed ID: 37217945
[TBL] [Abstract][Full Text] [Related]
13. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
14. Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells.
Huun J; Gansmo LB; Mannsåker B; Iversen GT; Øvrebø JI; Lønning PE; Knappskog S
BMC Cell Biol; 2017 Apr; 18(1):17. PubMed ID: 28415963
[TBL] [Abstract][Full Text] [Related]
15. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells.
Zhu Y; Wu J; Li S; Ma R; Cao H; Ji M; Jing C; Tang J
Cell Physiol Biochem; 2013; 32(5):1225-37. PubMed ID: 24335172
[TBL] [Abstract][Full Text] [Related]
16. PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression.
Xiang X; Yuan D; Liu Y; Li J; Wen Q; Kong P; Gao L; Zhang C; Gao L; Peng X; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):800-806. PubMed ID: 30020405
[TBL] [Abstract][Full Text] [Related]
17. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
18. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
Zhang Z; Lin G; Yan Y; Li X; Hu Y; Wang J; Yin B; Wu Y; Li Z; Yang XP
Oncogene; 2018 Jun; 37(25):3456-3470. PubMed ID: 29559745
[TBL] [Abstract][Full Text] [Related]
19. MDM2 344T>A polymorphism; could it be a predictive marker of anthracycline resistance?
Arfaoui A; Douik H; Kablouti G; Chaaben A; Handiri N; Zid Z; Ouni N; Zouiouch F; Ayari F; Mamoghli T; Bouassida J; Harzallah L; Guemira F
J BUON; 2016; 21(3):732-9. PubMed ID: 27569097
[TBL] [Abstract][Full Text] [Related]
20. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A; González I; Menendez S; Arpí O; Corominas JM; Servitja S; Tusquets I; Chamizo C; Rincón R; Espinosa L; Bigas A; Eroles P; Furriol J; Lluch A; Rovira A; Albanell J; Rojo F
Oncotarget; 2014 Jan; 5(1):196-210. PubMed ID: 24344116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]